All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Afucosylated antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 21, 2021
Details:
The unique advantage of the GlymaxX® technology is that a single GlymaxX® modified cell line is sufficient to produce both, completely fucosylated or afucosylated antibodies and those with an intermediate defined fuscosylation level.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Modified Oncolytic virus
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 09, 2020
Details:
The acquisition will enable Boehringer Ingelheim to further expand and accelerate its comprehensive program for the development of ATMP-based immuno-oncology therapies including the Vesicular Stomatitis Virus with modified glycoprotein platform and cancer vaccines platforms.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Plamotamab,Tafasitamab,Lenalidomide
Therapeutic Area: Oncology Product Name: XmAb 13676
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Xencor
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 11, 2020
Details:
Under the terms of the agreement, the companies plan to initiate a Phase 1/2 study evaluating the combination of tafasitamab, plamotamab and lenalidomide in patients with relapsed or refractory DLBCL.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Rhenium-188
Therapeutic Area: Oncology Product Name: Rhenium-188
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: NanoMab Technology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 27, 2020
Details:
The Heads of Terms will initiate a Strategic Partnership and Supply Agreement for the development of Rhenium-188 API solutions that are appropriate for labelling the NanoMab range of nanobodies for the production of therapeutic radiopharmaceuticals.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RCA-free adenoviral vectors
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Rznomics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 20, 2020
Details:
Under the terms of the agreement, Rznomics will use CEVEC’s cell line technology in combination with Rznomics’ proprietary trans-splicing ribozyme technology for manufacturing of gene therapies targeting various cancer indications.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): T-cell receptor-based cell therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Catalent Pharma Solutions
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 21, 2020
Details:
Under the terms of the agreement, Catalent will undertake transfer of T-knife´s platform process for T-cell receptor-based cell therapy at its site in Gosselies, Belgium, with the goal of manufacturing clinical batches for European trials in 2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GlymaxX
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 08, 2020
Details:
ProBioGen AG, has signed a commercial license agreement with Roche for applying ProBioGen’s proprietary GlymaxX® technology to boost the antibody’s ADCC anti-tumor activity.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
